Acquisition Momentum Aligned with AMETEK under a recent acquisition, LKC Technologies presents a scalable pathway for expanding RETeval adoption within AMETEK’s channels and portfolio, suggesting collaboration opportunities with existing medical device distributors and sales teams.

Clinical Benefit RETeval’s non-dilated, FDA-cleared ERG/VEP testing and user-friendly, color-coded reports address a critical gap in ophthalmic follow-up care, enabling you to pitch value propositions around improved progression risk assessment and patient cooperation.

Expansion Potential With prior growth efforts including US market expansion and leadership hires, there is demonstrated interest in scaling; sales outreach can target optometry practices, glaucoma clinics, and regional distributors to broaden device penetration.

Digital Readiness A tech stack leaning on popular collaboration and marketing tools (WordPress, Microsoft 365, analytics) indicates readiness for digital marketing, lead generation, and customer education campaigns to drive product awareness and adoptive selling.

Financial Signals Mid-market revenue range and modest funding indicate a growth-focused but cost-conscious segment; tailor value-as-a-service proposals, bundled offerings, and ROI-driven pricing to align with budget constraints of ophthalmology practices and multi-site networks.